Biogen Idec Plans Multiple Sclerosis Portfolio Expansion
This article was originally published in The Pink Sheet Daily
Executive Summary
Aside from the marketed Avonex and Tysabri, Biogen is pursuing three other treatments through partnerships and acquisitions.
You may also be interested in...
Genzyme Initiates Campath Phase III Study In Multiple Sclerosis
Firm and partner Bayer are on track to file alemtuzumab for relapsing-remitting MS in 2011, with a launch slated for 2012.
Genzyme Initiates Campath Phase III Study In Multiple Sclerosis
Firm and partner Bayer are on track to file alemtuzumab for relapsing-remitting MS in 2011, with a launch slated for 2012.
Biogen Idec Gets Potential Oral Tysabri Follow-on In UCB Deal
The company's second oral multiple sclerosis candidate employs the same mechanism as Tysabri and is set to enter Phase II early next year.